UetrechtJP. Idiosyncratic drug reactions: Possible role of reactive metabolites generated by leukocytes. Pharmacol Res1989; 6: 265–73.
2.
RileyRJMaggsJLLambertCKitteringhamNRParkBK. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil, and mianserin. Br J Clin Pharmacol1988; 26: 577–88.
3.
KitteringhamNRLambertCMaggsJLColbertJParkBK. A comparative study of the formation of chemically reactive drug metabolites by human liver microsomes. Br J Clin Pharmacol1988; 26: 13–21.
AcostaAMitchellBP. Metabolic activation and cytotoxicity of cyclophosphamide in primary cultures of postnatal rat hepatocytes. Biochem Pharmacol1981; 30: 3225–30.
6.
SpielbergSPGordonGBBlackDAGoldsteinDAHerlongHF. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med1981; 305: 722–7.
7.
ShearNHSpielbergSP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest1988; 82: 1826–32.
8.
RileyRJKitteringhamNRParkBK. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. Br J Clin Pharmacol1989; 28: 482–7.
9.
AdamsJVorheesCVMiddaughLD. Developmental neurotoxicity of anticonvulsants: Human and animal evidence on phenytoin. Neurotoxicol Teratol1990; 12: 203–14.
10.
JonesKLLacroRVJohnsonKAAdamsJ. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med1989; 320: 1661–6.
11.
BuehlerBADelimontDVan WaesMFinnellRH. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med1990; 322: 1567–72.
12.
Valproate, spina bifida, and birth defect registries. Lancet1988; 2: 1404–5.
13.
LindhoutDSchmidtD. In-utero exposure to valproate and neural tube defects. Lancet1986; 1: 1392–3.
14.
KallenBRobertEMastroiacovoPMartinez-FriasMLCastillaEECocchiG. Anticonvulsant drugs and malformations. Eur J Epidemiol1989; 5: 31–6.
15.
Epilepsy and spina bifida. Drug Ther Bull1990; 28: 59–60.
16.
RosaFW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med1991; 324: 674–7.
17.
Teratogenesis with carbamazepine. Lancet1991; 337: 1316–7.
18.
KanekoSOtaniKFukushimaYOgawaYNomuraYOnoT. Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. Epilepsia1988; 29: 459–67.
19.
KerrBMRettieAEEddyACLoiseauPGuyotMWilenskyAJ. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin Pharmacol Ther1989; 46: 82–93.
20.
MartzFFailingerCBlakeDA. Phenytoin teratogenesis correlation between embryopathic effect and covalent binding of putative arene oxide metabolites in gestational tissue. J Pharmacol Exp Ther1977; 203: 231–9.
RettieARRettenmeierAWHowaldWNBaillieTA. Cytochrome P-450-catalyzed formation of delta-4-VPA, a toxic metabolite of valproic acid. Science1987; 235: 890–3.
23.
LevyRHRettenmeierAWAndersonGDWilenskyAJFrielPNBaillieTA. Effects of polytherapy with phenytoin, carbamazepir and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther1990; 48: 225–35.
24.
EadieMJMcKinnonGEDunstanPRMacLaughlinDDickinsonRG. Valproate metabolism during hepatotoxicity associated with the drug. Q J Med1990; 77: 1229–40.
25.
AppletonREFarrellKApplegarthDADimmickJEWongLTKDavidsonAGF. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci1990; 17: 145–8.
26.
WoosleyRLDrayerDEReidenbergMMNiesASCarrKOatesJA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med1978; 298: 1157–9.
27.
UetrechtJPSweetmanBJWoosleyRLOatesJA. Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab Dispos1984; 12: 77–81.
28.
UetrechtJP. Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther1985; 232: 420–5.
29.
RubinRLUetrechtJPJonesJE. Cytotoxicity of oxidative metabolites of procainamide. J Pharmacol Exp Ther1987; 242: 833–41.
30.
CribbAESpielbergSP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos1990; 18: 784–7.
31.
RiederMJUetrechtJPShearNHSpielbergSP. Synthesis and in vitro toxicity of hydroxylamine metabolites of sulfonamides. J Pharmacol Exp Ther1988; 244: 724–8.
32.
RiederMJUetrechtJPShearNHCannonMMillerMSpielbergSP. Diagnosis of sulfonamide hypersensitivity reactions by in vitro “rechallenge” with hydroxylamine metabolites. Ann Intern Med1989; 110: 286–9.
33.
ShearNHSpielbergSP. In vitro evaluation of a toxic metabolite of sulfadiazine. Can J Physiol Pharmacol1985; 63: 1370–2.
34.
CribbAEMillerMLeederJSHillJSpielbergSP. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos1991; 19: 900–6.
35.
PirmohamedMColemanMDHussainFBreckenridgeAMParkBK. Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Br J Clin Pharmacol1991; 32: 303–10.
